Many Psoriasis Patients Undertreated for CV Risk Factors

This article originally appeared here.
Share this content:
Many Psoriasis Patients Undertreated for CV Risk Factors
Many Psoriasis Patients Undertreated for CV Risk Factors

(HealthDay News) – A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the July issue of the Journal of the American Academy of Dermatology.

Alexa B. Kimball, MD, from Harvard Medical School in Boston, and colleagues reviewed the medical histories, including glucose, lipid, and blood pressure levels, of 2,899 patients with moderate-to-severe psoriasis participating in three Phase 3 ustekinumab trials.

The researchers found that there were significant risk factors in patients with moderate-to-severe psoriasis, with 58.6 and 28.8% of patients, respectively, having two or more and three or more CV risk factors. The risk of CV events, based on Framingham risk score, was high for 18.6% of patients and intermediate for 12.3% of patients. A small proportion of patients with diabetes, hypertension, or hyperlipidemia were undiagnosed at baseline (2.3, 9.1, and 4.9%, respectively). A higher proportion were untreated at baseline (19.1, 21.8, and 38.6%, respectively), and the proportion achieving the treatment goal was not ideal (36.7, 59.6, and 69.7%, respectively).

"In summary, study findings highlight the fact that despite a growing recognition of the association between psoriasis and CV risk, a high proportion of patients with psoriasis severe enough to qualify for clinical trial participation have unrecognized or inadequately treated CV risk factors," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs